{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:34:02Z","timestamp":1761597242888},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1097\/nrl.0b013e3181dba5d3","type":"journal-article","created":{"date-parts":[[2010,12,9]],"date-time":"2010-12-09T06:07:58Z","timestamp":1291874878000},"page":"353-357","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacology of Antiepileptic Drugs in Clinical Practice"],"prefix":"10.1097","volume":"16","author":[{"given":"Joana","family":"Guimar\u00e3es","sequence":"first","affiliation":[]},{"given":"Jos\u00e9 Augusto Mendes","family":"Ribeiro","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-3-20210211","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1528-1157.1993.tb02126.x","article-title":"Some aspects of prognosis in the epilepsies: a review.","volume":"34","author":"Sander","year":"1993","journal-title":"Epilepsia"},{"key":"R2-3-20210211","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy.","volume":"242","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"R3-3-20210211","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1111\/j.1528-1157.1995.tb05996.x","article-title":"Antiepileptic drug mechanisms of action.","volume":"36","author":"Mcdonald","year":"1995","journal-title":"Epilepsia"},{"key":"R4-3-20210211","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1111\/j.1528-1157.1996.tb06038.x","article-title":"Update on the mechanism of action of antiepileptic drug.","volume":"37","author":"Meldrum","year":"1999","journal-title":"Epilepsia"},{"key":"R6-3-20210211","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1345\/aph.10417","article-title":"Newer therapies in the drug treatment of epilepsy.","volume":"36","author":"McAuley","year":"2002","journal-title":"Ann Pharmacother"},{"key":"R7-3-20210211","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1528-1157.1999.tb02029.x","article-title":"The pharmacologic basis of antiepileptic drug action.","volume":"40","author":"Rho","year":"1999","journal-title":"Epilepsia"},{"key":"R10-3-20210211","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/j.1528-1157.1999.tb02034.x","article-title":"Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis.","volume":"40","author":"Vreugdenhil","year":"1999","journal-title":"Epilepsia"},{"key":"R11-3-20210211","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1568007023339463","article-title":"Recent advances in the modulation of voltage-gated ion channels for the treatment of epilepsy.","volume":"1","author":"Cosford","year":"2002","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"R12-3-20210211","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2174\/1389450043345227","article-title":"Ion channels as important targets for antiepileptic drug design.","volume":"5","author":"Yogeeswari","year":"2004","journal-title":"Curr Drug Targets"},{"issue":"suppl 1","key":"R13-3-20210211","first-page":"S25","article-title":"Ion channels and epilepsy.","volume":"30","author":"Armijo","year":"2000","journal-title":"Rev Neurol"},{"key":"R15-3-20210211","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1528-1167.2006.00457.x","article-title":"Brain homocarnosine and seizure control of patients taking gabapentin or topiramate.","volume":"47","author":"Petroff","year":"2006","journal-title":"Epilepsia"},{"key":"R16-3-20210211","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1111\/j.1460-9568.2007.05533.x","article-title":"GABAergic mechanisms in absence epilepsy: a computational model of absence epilepsy simulating spike and wave discharges after vigabatrin in WAGRij rats.","volume":"25","author":"Bouwman","year":"2007","journal-title":"Eur J Neurosci"},{"key":"R17-3-20210211","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neulet.2007.01.038","article-title":"Absence seizures are reduced by the enhancement of GABA-ergic inhibition in the hippocampus in WAGRij rats.","volume":"416","author":"Tolmacheva","year":"2007","journal-title":"Neurosci Lett"},{"key":"R18-3-20210211","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pharmthera.2006.07.005","article-title":"Novel anticonvulsant drugs.","volume":"113","author":"Stefan","year":"2007","journal-title":"Pharmacol Ther"},{"key":"R20-3-20210211","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJM199601183340308","article-title":"Antiepileptic drugs.","volume":"334","author":"Brodie","year":"1996","journal-title":"N Engl J Med"},{"key":"R21-3-20210211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200115010-00001","article-title":"The star systems: overview and use in determining antiepileptic drug choice.","volume":"15","author":"Brodie","year":"2001","journal-title":"CNS Drugs"},{"key":"R22-3-20210211","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","article-title":"Therapeutic drug monitoring of the new antiepileptic drugs.","volume":"25","author":"Johannessen","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R23-3-20210211","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R24-3-20210211","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1528-1157.2000.tb00111.x","article-title":"Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed.","volume":"41","author":"Deckers","year":"2000","journal-title":"Epilepsia"},{"key":"R25-3-20210211","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1528-1167.2006.00585.x","article-title":"ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.","volume":"47","author":"Glauser","year":"2006","journal-title":"Epilepsia"},{"key":"R26-3-20210211","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/seiz.2000.0442","article-title":"Epilepsy after the first drug fails: substitution or add-on.","volume":"9","author":"Knaw","year":"2000","journal-title":"Seizure"},{"issue":"suppl 5","key":"R27-3-20210211","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.58.8_suppl_5.S2","article-title":"Staged approach to epilepsy management.","volume":"58","author":"Brodie","year":"2002","journal-title":"Neurology"},{"key":"R28-3-20210211","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11940-006-0019-5","article-title":"Seizure aggravation by antiepileptic drugs.","volume":"8","author":"Somerville","year":"2006","journal-title":"Curr Treat Options Neurol"},{"key":"R29-3-20210211","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pediatrneurol.2005.03.001","article-title":"Aggravation of epilepsy by antiepileptic drugs.","volume":"33","author":"Sazgar","year":"2005","journal-title":"Pediatr Neurol"},{"key":"R30-3-20210211","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1111\/j.1528-1167.2007.01201.x","article-title":"Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy.","volume":"48","author":"Otoul","year":"2007","journal-title":"Epilepsia"},{"key":"R31-3-20210211","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0163-7258(01)00122-X","article-title":"The mechanisms of action of commonly used antiepileptic drugs.","volume":"90","author":"Kwan","year":"2001","journal-title":"Pharmacol Ther"},{"key":"R32-3-20210211","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1528-1157.2002.32201.x","article-title":"Seizure reduction and quality of life improvements in people with epilepsy.","volume":"43","author":"Birbeck","year":"2002","journal-title":"Epilepsia"}],"container-title":["The Neurologist"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00127893-201011000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:25:01Z","timestamp":1618035901000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00127893-201011000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/nrl.0b013e3181dba5d3","relation":{},"ISSN":["1074-7931"],"issn-type":[{"value":"1074-7931","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}